Thus, based on strong evidence, the SGLT2 inhibitors dapagliflozin, empagliflozin, and more recently sotagliflozin (currently approved for the treatment of HF in the United States but not in the European Union) are recommended as first line therapy in patients with T2D and HF to reduce CV death and HF hospitalization [108]. Here, SLC5A2 is linked to type 2 diabetes mellitus.